Significantly Enriched Pathways. حسب Jiyong Zhang (2498740)

الموضوعات:

Health inequalities in the burden of IBD among WCBA. حسب Jiefeng Zhao (9090305)

الموضوعات:

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. حسب Jiefeng Zhao (9090305)

الموضوعات:

Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. حسب Jiefeng Zhao (9090305)

الموضوعات:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. حسب Jiefeng Zhao (9090305)

الموضوعات:

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. حسب Jiefeng Zhao (9090305)

الموضوعات:

Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. حسب Jiefeng Zhao (9090305)

الموضوعات:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. حسب Jiefeng Zhao (9090305)

الموضوعات:

Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation حسب Xiaoyu Shen (4715430)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Projected global leukemia burden, 1990-2050. حسب Chengjun Hu (588206)

الموضوعات:

Questionnaire description. حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

"…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …"